Paris-based Sanofi and Tarrytown, New York-based Regeneron Pharmaceuticals announced topline data for the companies’ pivotal Phase II trial of the PD-1 checkpoint inhibitor Libtayo (cemiplimab) in advanced basal cell carcinoma patients that had progressed on or could not tolerate previous hedgehog pathway inhibitor therapies.

India’s largest drugmaker, Sun Pharmaceutical Industries, is buying the skin cancer drug Odomzo from Switzerland-based Novartis for $175 million upfront.